ASBP
Aspire Biopharma·NASDAQ
--
--(--)
--
--(--)
8.02 / 10
Outperform
Capital flows are a standout strength, with a fund-flow score of 8.02/10 and consistently positive trends across all liquidity buckets (overall, block, small, medium, large, extra-large). This robust inflow may provide short-term momentum, but it must counteract the prevailing fundamental and technical headwinds.
Fund Flow Rating
What is the analyst consensus for ASBP?
- ASBP holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 8.02/10 (Outperform).
